Long-term Exon Skipping Studies With 2′-O-Methyl Phosphorothioate Antisense Oligonucleotides in Dystrophic Mouse Models
Antisense-mediated exon skipping for Duchenne muscular dystrophy (DMD) is currently tested in phase 3 clinical trials. The aim of this approach is to modulate splicing by skipping a specific exon to reframe disrupted dystrophin transcripts, allowing the synthesis of a partly functional dystrophin pr...
Main Authors: | Christa L Tanganyika-de Winter, Hans Heemskerk, Tatyana G Karnaoukh, Maaike van Putten, Sjef J de Kimpe, Judith van Deutekom, Annemieke Aartsma-Rus |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2012-01-01
|
Series: | Molecular Therapy: Nucleic Acids |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2162253116301020 |
Similar Items
-
Evaluation of 2’-Deoxy-2’-fluoro Antisense Oligonucleotides for Exon Skipping in Duchenne Muscular Dystrophy
by: Silvana M G Jirka, et al.
Published: (2015-01-01) -
Targeted Exon Skipping to Correct Exon Duplications in the Dystrophin Gene
by: Kane L Greer, et al.
Published: (2014-01-01) -
Dual Myostatin and Dystrophin Exon Skipping by Morpholino Nucleic Acid Oligomers Conjugated to a Cell-penetrating Peptide Is a Promising Therapeutic Strategy for the Treatment of Duchenne Muscular Dystrophy
by: Alberto Malerba, et al.
Published: (2012-01-01) -
Single Exon Skipping Can Address a Multi-Exon Duplication in the Dystrophin Gene
by: Kane Greer, et al.
Published: (2020-06-01) -
Repurposing Dantrolene for Long-Term Combination Therapy to Potentiate Antisense-Mediated DMD Exon Skipping in the mdx Mouse
by: Derek W. Wang, et al.
Published: (2018-06-01)